https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
s study may function as a prognostic indicator for HCC, which could provide evidence for clinical decision making.Unlike most other primary epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), exon 20 insertions, comprising approximately 4% to 10% of all EGFR mutations, are generally considered to be resistant to EGFR tyrosine kinase inhibitors (TKIs). However, EGFR exon 20 insertions are structurally and pharmacologically heterogeneous, with variability in their position and size having
Like
Comment
Share
